- $3.04bn
- $2.33bn
- $838.00m
- 51
- 25
- 62
- 43
RCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO and WCLC
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Update on Fruquintinib for Gastric Cancer in China
AnnouncementREG - Hutchmed China Ltd - Standard form for notification of major holdings
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Host Expert Call to discuss ITP
AnnouncementREG - Hutchmed China Ltd - LTIP and Share Option Scheme
AnnouncementREG - Hutchmed China Ltd - 2024 Interim Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - NDA Acceptance in China for Tazemetostat
AnnouncementRCS - Hutchmed China Ltd - Overseas Regulatory Announcement: Form F-3 Filing
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2024 HY Financial Results
AnnouncementRCS - Hutchmed China Ltd - Save the Date: HUTCHMED to Present R&D Updates
AnnouncementREG - Hutchmed China Ltd - European Commission Approval for FRUZAQLA
AnnouncementRCS - Hutchmed China Ltd - Lancet Publish Phase III ESLIM-01 Results
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase I Trial of HMPL-506
AnnouncementRCS - Hutchmed China Ltd - Nature Medicine Publish Phase III FRUTIGA Results
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Presentations at 2024 ASCO Annual Meeting
Announcement